Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

DxS launches PI3K mutation test for cancer drug trials

This article was originally published in Clinica

Executive Summary

DxS has launched a test to detect mutations in the PIK3CA oncogene, for use in clinical trials of cancer drugs. "We would expect that most, if not all companies developing drugs that target the EGFR pathway in breast cancer would want to assess this particular oncogene," the Manchester, UK firm's CEO Stephen Little said, as these mutations are seen in up to 40% of breast cancer patients. He hopes that the biomarker will prove useful, "and at that time we will translate this from a research tool into a companion diagnostic". This will probably take two to three years, he said, depending on the timing of clinical trials. PI3K mutations could also predict tamoxifen sensitivity or resistance, but this has not been confirmed.

Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

MT041317

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel